While aCL-IgA and aβ2GPI-IgA were included in the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria in 2012 and the 2019 EULAR/ACR classification criteria [33,34], they remain excluded from the APS classification criteria in the 2023 ACR/EULAR guidelines [35]. Here, CD79A is linked to autoimmune polyendocrinopathy.